SCHEMBL24258030

SCHEMBL24258030

O=[N+]([O-])c1cc(Cc2nc(-c3ccc(Cl)nc3)no2)ccc1Cl

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.48
ERCC1 P07992 1/20 0.45
ERCC4 Q92889 1/20 0.45
GAA P10253 2/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
MAPK1 P28482 5/20 0.41
TSHR P16473 4/20 0.41
KMT2A Q03164 3/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
MEN1 O00255 2/20 0.41
LMNA P02545 1/20 0.41
CASP3 P42574 1/20 0.41
SMN1; SMN2 Q16637 5/20 0.40
DHFR P00374 1/20 0.40
ALOX15 P16050 1/20 0.40
RAB9A P51151 5/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26004919 0.90 MAPT (0.47) MAPTERCC1ERCC4GAACYP1A2
SCHEMBL24258075 0.84 ERCC1 (0.52) MAPTERCC1ERCC4GAACYP1A2
SCHEMBL26004727 0.81 MAPT (0.47) MAPTERCC1ERCC4GAACYP1A2
SCHEMBL24258045 0.78 CYP1A2 (0.66) ERCC1ERCC4GAACYP1A2CYP3A4
SCHEMBL24258078 0.78 CYP1A2 (0.50) MAPTERCC1ERCC4GAACYP1A2
SCHEMBL24258005 0.76 CYP1A2 (0.51) MAPTERCC1ERCC4GAACYP1A2
SCHEMBL2705188 0.76 MAPT (0.60) MAPTGAAMAPK1KMT2AMEN1
SCHEMBL24258025 0.76 CYP1A2 (0.53) ERCC1ERCC4GAACYP1A2CYP3A4
SCHEMBL24258043 0.75 S1PR1 (0.59) ERCC1ERCC4GAACYP1A2CYP3A4
SCHEMBL24258080 0.75 ERCC1 (0.56) MAPTERCC1ERCC4GAACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265082-A1 SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-08-24 US disclosed
US-20230265082-A1 SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-08-24 US disclosed
WO-2022035805-A1 SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230265082-A1 SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 USP28, USP1, USP18 MAPT 977/4885ERCC1 2832/4885ERCC4 1843/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.